Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary
Search for other papers by Jennifer Shih in
Current site
Google Scholar
PubMed
Search for other papers by Babar Bashir in
Current site
Google Scholar
PubMed
Search for other papers by Karen S. Gustafson in
Current site
Google Scholar
PubMed
Search for other papers by Mark Andrake in
Current site
Google Scholar
PubMed
Search for other papers by Roland L. Dunbrack in
Current site
Google Scholar
PubMed
Search for other papers by Lori J. Goldstein in
Current site
Google Scholar
PubMed
From Fox Chase Cancer Center, Temple University Heath System, Philadelphia; Abington Memorial Hospital, Abington; and Molecular Therapeutics Research Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Search for other papers by Yanis Boumber in
Current site
Google Scholar
PubMed
Next-generation sequencing of primary and metachronous metastatic cancer lesions may impact patient care. We present a case of relapsed metastatic breast cancer with a dominant pulmonary lesion originally identified as lung adenocarcinoma. A 72-year-old, never-smoker woman with a protracted cough was found to have a large lung mass and regional lymphadenopathy on a chest CT. Lung mass biopsy showed adenocarcinoma with focal TTF-1 (thyroid transcription factor 1) positivity, favoring a lung primary. In addition to stereotactic brain radiation for cerebral metastases, she was started on carboplatin/pemetrexed. As part of the workup, the tumor was analyzed by a 50-gene targeted mutation panel, which detected 3 somatic mutations: ERBB2 (HER2) D769H activating missense mutation, TP53 Y126 inactivating truncating mutation, and SMARCB1 R374Q missense mutation. Of note, the patient had a history of stage IIA triple-negative grade 3 invasive ductal carcinoma of the left breast 1.5 years ago and received neoadjuvant chemotherapy and adjuvant radiation, and underwent a lumpectomy. Further analysis of her primary breast tumor showed a mutational profile identical to that of the lung tumor. Fluorescence in situ hybridization revealed HER2 amplification in the lung tumor, with a HER2/CEP17 ratio of 3.9. The patient was diagnosed with recurrent HER2-positive metastatic breast carcinoma with a coexisting ERBB2 (HER2) activating mutation. Chemotherapy was adjusted to include dual HER2-targeted therapy containing trastuzumab and pertuzumab, resulting in an ongoing partial response. This case demonstrates that a unique genetic mutational profile can clarify whether a tumor represents a metastatic lesion or new malignancy when conventional morphological and immunohistochemical methods are indeterminate, and can directly impact treatment decisions.
© 2019-2024 National Comprehensive Cancer Network